Roth Capital Initiates Coverage on Nektar Therapeutics (NKTR)
Nektar Therapeutics traded down 1.57% on Thursday, hitting $6.89. Nektar Therapeutics has a 52-week low of $4.07 and a 52-week high of $10.83. The company’s market cap is $789.7 million.
Nektar Therapeutics last posted its quarterly earnings results on Wednesday, May 2nd. The company reported ($0.36) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.33) by $0.03. Nektar Therapeutics’s revenue was up 58.4% compared to the same quarter last year. Analysts expect that Nektar Therapeutics will post $-0.32 EPS next quarter.
Separately, analysts at Jefferies Group (NYSE: JEF) initiated coverage on shares of Nektar Therapeutics in a research note to investors on Wednesday. They set a “buy” rating on the stock.
Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients.